Assessing the impact of the amendment to national genetic directory testing guidelines, April 2022

Introduction: Identification of patients with a breast cancer genetic predisposition is crucial for informed decision making. In April 2022 the directory testing criteria for breast cancer were amended, extending testing to all patients below 40 with a grade 2 cancer for any receptor status. We assessed the impact on our mainstream referral pathway to the regional genetic team and assessed the proportion under 40 found to have a genetic mutation.